The pharmaceutical companies Acceleron Pharma and Fulcrum Therapeutics are working together to identify small molecules that can be used to treat lung diseases, including pulmonary hypertension (PH).

Through this collaboration, Acceleron will be able to access Fulcrum’s proprietary equipment and target identification platform to identify small molecules capable of regulating gene expression that are known to affect specific cellular pathways associated with the development and progression of pulmonary disease.

Pursuant to the agreement, Acceleron is responsible for the development and commercialization of any therapeutic candidates identified through the Fulcrum platform. Fulcrum will receive a one-time contribution of $ 10 million, in addition to any reimbursement for relevant research and development costs.